NTLA
NASDAQIntellia Therapeutics Inc.
News · 26 weeks52-43%
2026-04-192026-10-11
Mix1990d
- Other8(42%)
- SEC Filings5(26%)
- Insider3(16%)
- Earnings1(5%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- PRIntellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerCAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company’s translational, development, regulatory and medical affair
- INSIDERSEC Form 4 filed by Intellia Therapeutics Inc.4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- ANALYSTBarclays initiated coverage on Intellia Therapeutics with a new price targetBarclays initiated coverage of Intellia Therapeutics with a rating of Underweight and set a new price target of $8.00
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 44,450 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee o
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027. Additionally, FDA has advised the company that it is not currently
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 163,100 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee
- PRIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including a planned U.S. approval and commercial launch of lonvoguran ziclumeran (lonvo-z) as a one-time treatment for patients with hereditary angioedema (HAE). "Lonvo-z has t
- PRIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET. A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days. About Intellia TherapeuticsIntellia Therapeutics, Inc. (NASDAQ:NTLA) is a l
- INSIDERPresident and CEO Leonard John M sold $286,819 worth of shares (22,675 units at $12.65) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,147,064 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- SECSEC Form 144 filed by Intellia Therapeutics Inc.144 - Intellia Therapeutics, Inc. (0001652130) (Subject)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 38,200 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of
- SECSEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)
- SECSEC Form 10-Q filed by Intellia Therapeutics Inc.10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesPositive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patientsEnded second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least into 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (G
- PRIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesCAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conferen
- INSIDEREVP, Chief Financial Officer Dulac Edward J Iii sold $91,249 worth of shares (8,111 units at $11.25), decreasing direct ownership by 5% to 148,175 units (SEC Form 4) to satisfy withholding tax4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- ANALYSTIntellia Therapeutics downgraded by Wolfe Research with a new price targetWolfe Research downgraded Intellia Therapeutics from Peer Perform to Underperform and set a new price target of $9.00
- INSIDERVP, Chief Accounting Officer Dube Michael P sold $44,316 worth of shares (2,641 units at $16.78), decreasing direct ownership by 4% to 66,886 units (SEC Form 4) (tax liability)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDEREVP, Chief Financial Officer Dulac Edward J Iii sold $84,186 worth of shares (4,677 units at $18.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 156,286 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee o
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaData from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Cl
NTLA FAQ
7 questionsWhat does Intellia Therapeutics Inc. do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...Where does NTLA stock trade?
Intellia Therapeutics Inc. (NTLA) is listed on NASDAQ.What sector and industry is NTLA in?
Intellia Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Intellia Therapeutics Inc. go public?
Intellia Therapeutics Inc. (NTLA) completed its IPO in 2016.What are analysts saying about NTLA?
Intellia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Underweight with a $800.00 price target on 2026-10-06. Recent price targets range from $500.00 to $1400.00.What companies are similar to NTLA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation). Compare NTLA side-by-side with any of them on Quantisnow.How can I track NTLA on Quantisnow?
Quantisnow aggregates Intellia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NTLA to receive live email and push alerts on every new disclosure.